Befreiender Konzernabschluss Zum Geschäftsjahr Vom 01.04.2021 Bis Zum 31.03.2022 - Takeda GmbHKonstanz
| Published date | 02 Enero 2023 |
| Section | Rechnungslegung / Finanzberichte |
| Issuer | Takeda GmbHKonstanz |
Takeda GmbH
Konstanz
Befreiender Konzernabschluss zum Geschäftsjahr vom 01.04.2021 bis zum 31.03.2022
Takeda Pharmaceutical Company Limited
Osaka/Japan
Annual Securities Report From April 1, 2021 to March 31, 2022
(The 145th Fiscal Year)
As used in this annual securities report, references to the “Company,” “Takeda,” “we,” “us” and “our” are to Takeda Pharmaceutical Company Limited and, except as the context otherwise requires, its consolidated subsidiaries.
In this annual securities report, we present our audited consolidated financial statements as of March 31, 2021 and 2022 and for the fiscal years ended March 31, 2021 and 2022. Our consolidated financial statements are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). The term IFRS also includes International Accounting Standards (“IAS”) and the related interpretations of the committees (Standard Interpretations Committee and International Financial Reporting Interpretations Committee).
As used in this annual securities report, “ADS” means an American Depositary Share, representing 0.5 shares of the Company’s common stock, and “ADR” means an American Depositary Receipt evidencing one or more ADSs.
As used in this annual securities report, except as the context otherwise requires, the “Companies Act” means the Companies Act of Japan.
Amounts shown in this annual securities report have been rounded to the nearest indicated digit unless otherwise specified. In tables and graphs with rounded figures, sums may not add up due to rounding.
TABLE OF CONTENTS
Part 1. Information on Takeda
I. Overview of Takeda
1. Key Financial Data
2. History
3. Business Overview
4. Overview of Subsidiaries and Associates
5. Employees
II. Operation and Financial Review and Prospects
1. Management Policy, Management Environment and Management Issues
2. Risk Factors
3. Management's Analysis of Financial Position, Operating Results and Cash Flows
4. Material Contracts
5. Research and Development
III. Property, Plant, and Equipment
1. Overview of Capital Expenditures
2. Major Facilities
3. Plans for New Facility Construction, Old Facility Disposal, etc.
IV. Information on the Company
1. Information on the Company's Shares
2. Acquisition of Treasury Stock and Other Related Status
3. Dividend Policy
4. Corporate Governance
V. Financial Information
1. Consolidated Financial Statements and Others
2. Unconsolidated Financial Statements and Others
VI. Overview of Administrative Procedures for Shares of the Company
VII. Reference Information on the Company
Part 2. Information on Guarantors for Takeda
Independent Auditor's Report
Internal Control Report
Confirmation Letter
| [Document Filed] | Annual Securities Report |
| [Applicable Law] | Article 24, paragraph 1 of the Financial Instruments and Exchange Act of Japan |
| [Filed with] | Director, Kanto Local Finance Bureau |
| [Filing Date] | June 29, 2022 |
| [Fiscal Year] | The 145th Fiscal Year (from April 1, 2021 to March 31, 2022) |
| [Company Name] | Takeda Pharmaceutical Company Limited |
| [Title and Name of Representative] | Christophe Weber, Representative Director, President & Chief Executive Officer |
| [Address of Head Office] | 1-1, Doshomachi 4-chome, Chuo-ku, Osaka |
| (The above address is the registered head office location and the ordinary business operations are conducted at the “Nearest Place of Contact”) | |
| [Telephone Number] | Not applicable |
| [Name of Contact Person] | Not applicable |
| [Nearest Place of Contact] | 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo (Global Headquarters) |
| [Telephone Number] | +81-3-3278-2111 (Main telephone number) |
| [Name of Contact Person] | Norimasa Takeda, Chief Accounting Officer & Corporate Controller, Global Finance |
| [Place for Public Inspection] | Takeda Pharmaceutical Company Limited (Global Headquarters) (1-1, Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo) |
| Stock Exchange, Inc. (2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo) | |
| Nagoya Stock Exchange, Inc. (8-20, Sakae 3-chome, Naka-ku, Nagoya) | |
| Fukuoka Stock Exchange (14-2, Tenjin 2-chome, Chuo-ku, Fukuoka) | |
| Sapporo Stock Exchange (14-1, Minamiichijonishi 5-chome, Chuo-ku, Sapporo) |
Part 1. Information on Takeda
I. Overview of Takeda
1. Key Financial Data
(1) Consolidated Financial Data
| JPY (millions), unless otherwise indicated | |||||
| Fiscal Year | 141st March | 142nd | 143rd | 144th | 145th |
| Year Ended | 31, 2018 | March 31, 2019 | March 31, 2020 | March 31, 2021 | March 31, 2022 |
| Revenue | ¥ 1,770,531 | ¥ 2,097,224 | ¥ 3,291,188 | ¥ 3,197,812 | ¥ 3,569,006 |
| Profit (loss) before tax | 217,205 | 127,612 | (60,754) | 366,235 | 302,571 |
| Net profit for the year | 186,708 | 135,080 | 44,290 | 376,171 | 230,166 |
| Net profit attributable to owners of the Company | 186,886 | 135,192 | 44,241 | 376,005 | 230,059 |
| Total comprehensive income (loss) for the year | 242,664 | 121,595 | (199,419) | 697,416 | 824,427 |
| Total equity | 2,017,409 | 5,185,991 | 4,727,486 | 5,177,177 | 5,683,523 |
| Total assets | 4,106,463 | 13,792,773 | 12,821,094 | 12,912,293 | 13,178,018 |
| Equity attributable to owners of the Company per share (JPY) | 2,556.51 | 3,332.94 | 3,032.22 | 3,308.93 | 3,665.61 |
| Basic earnings per share (JPY) | 239.35 | 140.61 | 28.41 | 240.72 | 147.14 |
| Diluted earnings per share (JPY) | 231.56 | 139.82 | 28.25 | 238.96 | 145.87 |
| Ratio of equity attributable to owners of the Company to total assets (%) | 48.6 | 37.6 | 36.8 | 40.1 | 43.1 |
| Return on equity attributable to owners of the Company (%) | 9.6 | 3.8 | 0.9 | 7.6 | 4.2 |
| Price earnings ratio (Times) | 21.7 | 32.2 | 116.4 | 16.6 | 23.8 |
| Net cash from (used in) operating activities | 377,854 | 328,479 | 669,752 | 1,010,931 | 1,123,105 |
| Net cash from (used in) investing activities | (93,342) | (2,835,698) | 292,119 | 393,530 | (198,125) |
| Net cash from (used in) financing activities | (326,226) | 2,946,237 | (1,005,213) | (1,088,354) | (1,070,265) |
| Cash and cash equivalents at the end of the year | 294,522 | 702,093 | 637,614 | 966,222 | 849,695 |
| Number of employees (Number of persons) | 27,230 | 49,578 | 47,495 | 47,099 | 47,347 |
Notes:
(1) The consolidated financial statements have been prepared and presented in accordance with International Financial Reporting Standards (IFRS).
(2) All figures shown are rounded to the nearest million JPY.
(2) Unconsolidated Financial Data
| JPY (millions), unless otherwise indicated | |||||
| Fiscal Year | 141st | 142nd | 143rd | 144th | 145th |
| Year Ended | March 31, 2018 | March 31, 2019 | March 31, 2020 | March 31, 2021 | March 31, 2022 |
| Net sales | ¥ 659,462 | ¥ 651,347 | ¥ 616,288 | ¥ 602,557 | ¥ 764,301 |
| Ordinary income | 125,944 | 17,514 | 72,252 | 50,010 | 550,876 |
| Net income | 187,004 | 88,231 | 130,626 | 247,513 | 324,450 |
| Share capital | 77,914 | 1,643,585 | 1,668,123 | 1,668,145 | 1,676,263 |
| Total number of shares issued (Thousands of shares) | 794,688 | 1,565,006 | 1,576,374 | 1,576,388 | 1,582,253 |
| Total equity | 1,565,913 | 4,647,171 | 4,549,000 | 4,434,889 | 4,294,899 |
| Total assets | 2,948,562 | 9,534,645 | 10,289,304 | 10,856,450 | 9,641,648 |
| Net assets per share (JPY) | 2,002.29 | 2,987.94 | 2,919.21 | 2,835.81 | 2,769.31 |
| Dividend per share (JPY) | 180.00 | 180.00 | 180.00 | 180.00 | 180.00 |
| [Interim dividend per share (JPY)] | [90.00] | [90.00] | [90.00] | [90.00] | [90.00] |
| Basic earnings per share (JPY) | 239.47 | 91.76 | 83.88 | 158.45 | 207.50 |
| Diluted earnings per share (JPY) | 239.18 | 91.72 | 83.87 | 158.44 | 207.50 |
| Equity ratio (%) | 53.1 | 48.7 | 44.2 | 40.8 | 44.5 |
| Return on equity (%) | 12.1 | 2.8 | 2.8 | 5.5 | 7.4 |
| Price earnings ratio (Times) | 21.6 | 49.3 | 39.4 | 25.1 | 16.9 |
| Payout ratio (%) | 75.2 | 196.2 | 214.6 | 113.6 | 86.7 |
| Number of employees (Number of persons) | 5,461 | 5,291 | 5,350 | 4,966 | 5,149 |
| Total shareholders return [Comparative indicator: TOPIX Net Total Return](%) | 102.6 [115.9] | 93.3 [110.0] | 73.6 [99.6] | 90.0 [141.5] | 84.1 [144.3] |
| Highest stock price (JPY) | 6,693 | 5,418 | 4,625 | 4,365 | 4,115 |
| Lowest stock price (JPY) | 5,105 | 3,498 | 2,895 | 3,119 | 2,993 |
Notes:
(1) All figures shown are rounded to the nearest million JPY.
(2) We have adopted Accounting Standard for Revenue Recognition (ASBJ Statement No.29 issued on March 31, 2020) at the beginning of the 145th fiscal year, and financial data presented for the 145th fiscal year has been adjusted.
(3) The highest and lowest stock prices are from the first section of the Tokyo Stock Exchange.
2. History
| June | 1781 | Started business selling Japanese and Chinese medicines |
| May | 1871 | Began import of Western medicines |
| August | 1914 | Set up research division |
| October | 1915 | Established Takeda Pharmaceutical Company (currently the Osaka Plant) |
| August | 1921 | Established Daigo Nutritive Chemicals, Ltd. (currently Nihon Pharmaceutical Co., Ltd., a consolidated subsidiary) |
| June | 1922 | Established Takeda Pure Chemicals Ltd. (later renamed to Wako Pure Chemical Industries, Ltd. in October 1947 and divested in April 2017) |
| January | 1925 | Established Chobei Takeda & Co., Ltd. |
| August | 1943 | Changed name to Takeda Pharmaceutical Industries, Ltd. |
| May | 1946 | Established the Hikari Plant in Yamaguchi prefecture |
| May | 1949 | Listed on the Tokyo Stock Exchange and Osaka Exchange |
| August | 1962 | Established Takeda Pharmaceuticals Taiwan, Ltd. (currently a consolidated subsidiary) in Taiwan |
| April | 1984 | Established dual headquarters in Osaka and Tokyo |
| May | 1985 | Established TAP Pharmaceuticals Inc., a joint venture with Abbott Laboratories Inc., in the U.S. (TAP Pharmaceuticals was first a wholly owned subsidiary according to the business reorganization in April 2008, and then, |
Um weiterzulesen
FORDERN SIE IHR PROBEABO AN